ArticleFrontiers in immunology2025
The effects of cryopreservation on PBMCs transcriptome profile.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Can Complex 3D Models Effectively Replace 2D and Animal Models to Investigate the Microbe-Tumor-Immune Axis in Pancreatic Cancer Studies?Nutrients · 2026Review
- A standardized single-tube 17-color spectral flow cytometry workflow for integrated immunophenotyping of human PBMCs and mixed co-culture systems.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryopreservation is a key method for long-term storage of biological specimens. The development of optimal cryopreservation and recovery conditions will minimize storage-related damage. The effect of the cryopreservation and recovery condition we used on peripheral blood mononuclear cells (PBMCs) has previously been evaluated using microarray analysis. The emerging single-cell RNA sequencing (scRNA-seq) technology enables deeper exploration of cellular heterogeneity and function. In the current study, we further optimized the cryopreservation and recovery procedure based on cell viability of PBMC cryopreserved for one-year evaluated using trypan blue staining and propidium iodide (PI) staining with FACS. The procedure was further validated by scRNA-seq using PBMC cryopreserved for two different lengths of time: six and 12 months, in comparison with fresh cells. We identified six major immune cell types from both fresh and recovered cryopreserved PBMCs, including monocytes, dendritic cells (DCs), natural killer (NK) cells, CD4+ T cells, CD8+ T cells, and B cells. The cell viability of all identified immune cell types was relatively stable after both six and 12 months of cryopreservation; however, the number of cells sequenced in the scRNA-seq data declined significantly by ~32% after 12 months of cryopreservation, suggesting reduced scRNA-seq cell capture efficiency. Furthermore, the transcriptome profiles of cryopreserved samples did not show substantial perturbation over the 12-month testing period, although a few key genes involved in AP-1 complex, stress response or response to calcium ion exhibited significant change, but with very small scale (< two folds). In conclusion, even though we observed a reduction of scRNA-seq cell capture efficiency after 12-month cryopreservation, our results demonstrated that the optimized cryopreservation and recovery procedure has minimal effect on PBMC viability, population composition and transcriptomic profiles after 6 or 12 months of storage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.